Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + diclofenac is a combination drug regimen investigated for the treatment of acute renal colic. Lidocaine is a small-molecule local anesthetic and antiarrhythmic that acts by blocking voltage-gated sodium channels, providing visceral and central analgesia. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, to reduce prostaglandin synthesis and provide sustained pain relief. This specific combination, involving intravenous lidocaine and intramuscular diclofenac, was evaluated in a Phase 2 clinical trial (NCT05653401) sponsored by the University of Monastir in Tunisia, where it was compared against magnesium sulfate and placebo controls in an emergency department setting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + diclofenac.